OASIS Oral Semaglutida: New 2026 Data on the Tablet Version

If you follow the world of weight loss medications, you have probably heard about injectable semaglutida. But there is a version that is gaining more and more space and deserves attention. The oral semaglutida, the one you take with a glass of water and that is it. Recently, the OASIS study brought updated 2026 data that renews interest in this option. Here is what changed, what the numbers show, and what it means in practice for anyone considering adding this treatment to their life.

What the OASIS study is

OASIS is a phase 3 clinical trial that evaluates the efficacy and safety of semaglutida administered orally at 50 mg doses. The full name of the study involves assessing weight loss in adults with obesity or who are overweight with at least one weight-related comorbidity. The trial is randomized, double-blind, and placebo-controlled, which gives more weight to the results we are about to discuss.

Participants were followed over 68 weeks. This is a considerably long period for a weight loss study, and it allows observation not just of the initial drop on the scale, but also of how well those results hold up over time.

The numbers that caught attention

The data that most caught the attention of the medical community and patients was an average loss of 15% of body weight after 68 weeks of treatment. For comparison, many similar medications on the market offer losses around 10% to 12% over the same timeframe. The difference may seem small in percentage terms, but in practice it represents extra kilograms taken off the body, which directly impacts metabolic health and quality of life.

Beyond that, a significant portion of participants managed to maintain the weight loss after the active treatment phase. This is a point that deserves emphasis because one of the biggest challenges with any weight loss strategy is exactly avoiding the regain of lost weight.

How oral semaglutida works in the body

Semaglutida is a GLP-1 receptor agonist, a hormone that the intestine naturally releases after meals. This hormone sends satiety signals to the brain, slows down stomach emptying, and helps control blood sugar levels. When you take the tablet version, the substance is absorbed through the stomach lining and follows the same biological pathway as the injectable version.

The practical advantage of the oral route is obvious. No needle, no daily injection. There are 28 tablets per pack, taken once a day, on an empty stomach, at least 30 minutes before the first meal of the day. For many people, this makes adherence to long-term treatment easier, and that is precisely one of the biggest challenges when it comes to medication-assisted weight loss.

Who can use it

Oral semaglutida is currently approved in some countries for type 2 diabetes treatment and is gradually earning approvals for weight loss in people with obesity or who are overweight with related complications. Like any medication, it must be prescribed by a doctor who evaluates the individual history, including preexisting conditions, current medications, and realistic treatment goals.

The most common side effects involve the gastrointestinal tract, such as nausea and abdominal discomfort, especially in the first few weeks of use. These effects are generally mild and transient, tending to decrease as the body adapts. That is why professional follow-up is so important to adjust the dose and monitor the response.

The role of follow-up in treatment success

Efficacy data like OASIS is encouraging, but it needs context. The study was conducted with regular follow-up, dietary guidance, and clinical monitoring. That means participants were not alone in the process. They had support.

This is a lesson worth bringing into real life. Taking the medication helps, but combining it with mindful eating and regular physical activity noticeably enhances the results. Many patients who use semaglutida report that the ease of controlling hunger and the urge to eat at odd hours completely changes the dynamics of the day, making choices that once seemed impossible suddenly feel manageable.

Having a tool that helps you log what you eat, monitor symptoms, and track progress makes a real difference. Ozempro, for example, lets you follow your treatment routine, log adverse events, and keep everything organized in one place. If you are interested in understanding how an app can help in this process, you can take a quick personalized assessment right here.

Even people with recognized discipline find in digital support a way to maintain consistency. Logging weight, meals, and daily energy creates a history that a doctor can use to adjust doses and spot patterns. Ozempro was designed precisely for this. To work as a practical ally in the daily life of anyone going through treatment.

What to expect from 2026 and the years ahead

The OASIS data reinforces that oral semaglutida is not just a viable alternative, but an option with competitive numbers compared to the injectable versions. The pharmaceutical industry continues investing in research on combinations and dosages, and more options will likely reach the Brazilian market in the coming years.

For anyone seeking a sustainable weight loss path with scientific support, staying informed about these updates is part of the process. Medication is not a magic solution, but when well-indicated and properly followed, it opens doors that once seemed locked.

Talk to your doctor about the available options and ask whether oral semaglutida makes sense for your case. And if you want to better organize your routine during treatment, using a tracking app can make life much simpler. Ozempro helps keep everything on screen, making it easier to have a good dialogue with your doctor at every appointment.